广州思安信生物技术有限公司

Sianxin Biotech is a clinical-stage biotechnology company headquartered in Guangzhou, China, dedicated to the research and development of next-generation vaccines. The company utilizes a proprietary parainfluenza virus 5 (PIV5) vector platform to develop vaccines that can be administered intranasally, inducing both systemic and mucosal immunity. Its lead candidate is a nasal spray COVID-19 vaccine that has progressed through Phase 2 clinical trials. Beyond COVID-19, Sianxin is advancing a robust pipeline targeting respiratory syncytial virus (RSV), influenza, and other infectious diseases. The company has secured significant backing from prominent investors like Hillhouse Capital and Legend Capital to support its clinical programs and manufacturing scale-up.